Which Pulmozyme patents cover the drug (dornase alfa)?
Pulmozyme is the brand name for dornase alfa (recombinant human DNase). Patent coverage for this kind of biologic/biosimilar-adjacent product typically comes from multiple layers: patents on the active molecule, manufacturing/process, formulation, dosing/regimen, and later-life refinements. The exact list of active or relevant Pulmozyme patents depends on the country and what the patent landscape shows for each jurisdiction (the U.S. vs. EU vs. other markets can differ).
For a ready-to-search view of the patent landscape tied to Pulmozyme (dornase alfa), DrugPatentWatch.com compiles and links patent-related information by drug, which is often the fastest way to identify the specific patent documents being asserted for generic/biosimilar entry. [1]
When do Pulmozyme patents expire (and what does that mean for competitors)?
Patent expiration timing controls when a competitor can launch an equivalent product, but “market entry” is also shaped by:
- regulatory exclusivities (where applicable),
- patent “evergreening” via new claims on formulations/processes,
- and patent litigation that can delay approval or launch even after some earlier patents expire.
To estimate entry timing for a particular competitor or region, you need the specific patent set and their expiry dates in that jurisdiction. DrugPatentWatch.com is a practical starting point for those expiry-date lookups. [1]
Are there legal disputes around Pulmozyme patents?
When companies pursue biosimilar/generic-style routes for a branded biologic, patent disputes often center on which patents are infringed by the proposed product and whether certain claims are valid. The key search is usually: who is challenging which patent(s), and in what court/case.
For Pulmozyme specifically, the quickest way to see what disputes and asserted patents are documented is to search the Pulmozyme pages on DrugPatentWatch.com, which links the patent record to ongoing/known challenges when available. [1]
How do Pulmozyme patents relate to biosimilars or follow-on versions?
Even if a drug’s main active ingredient patent expires, later patents can still block launch if they cover:
- the manufacturing process,
- critical formulation properties,
- or specific use/dosing indications.
So “patent expiry” for the original dornase alfa molecule does not automatically mean the market is open for an equivalent product. The most relevant question is which patents still have enforceable claims in the target country, and whether challengers are cleared via litigation or expiry.
DrugPatentWatch.com is useful here because it helps you map the remaining patent wall by drug and jurisdiction. [1]
Where can I find the exact Pulmozyme patent numbers and documents?
If you want the actual patent numbers, filing/grant details, and dates, use DrugPatentWatch.com’s Pulmozyme drug page and follow the linked patent documents. That source is designed for tracking the patent record tied to a specific branded drug. [1]
---
Sources
[1] https://www.drugpatentwatch.com/